Etanercept in erythema nodosum leprosum
An. bras. dermatol
;
92(4): 575-577, July-Aug. 2017. graf
Article
Dans Anglais
| LILACS
| ID: biblio-1038255
ABSTRACT
Abstract One of the biggest challenges in treating leprosy is the control of reaction events. Patients with lepromatous leprosy may present reaction type II, or erythema nodosum leprosum, during treatment, and this reaction can remain in a recurrent form after being released from the hospital, requiring the use of thalidomide and/or prednisone for long periods of time, in turn increasing the risk of side effects. Two reports of the use of antiTNF to treat erythema nodosum leprosum were found in the literature. A good response was found after an assay with infliximab and etanercept. This study reports on a patient with lepromatous leprosy and recurrent reaction, controlled by using etanercept and a 10-month follow-up, with the interruption of thalidomide and the maintenance of prednisone at 10 mg/day.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Lèpre lépromateuse
/
Anti-inflammatoires non stéroïdiens
/
Érythème noueux
/
Étanercept
Limites du sujet:
Adulte
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
An. bras. dermatol
Thème du journal:
Dermatologie
Année:
2017
Type:
Article
Pays d'affiliation:
Brésil
Institution/Pays d'affiliation:
Santa Casa de Misericórdia do Rio de Janeiro/BR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS